Donor mesenchymal stem cells trigger chronic graft-versus-host disease following minor antigen-mismatched bone marrow transplantation by Yoko Ogawa et al.
1 
 
Donor mesenchymal stem cells trigger chronic graft-versus-host disease 
following minor antigen-mismatched bone marrow transplantation  
*Yoko Ogawa1, *Satoru Morikawa2, 3, Hideyuki Okano3, Yo Mabuchi3, 4, Sadafumi Suzuki3,
Tomonori Yaguchi5, Saori Yaguchi1, Takaaki Inaba1, Shinichiro Okamoto, Yutaka 
Kawakami5, Kazuo Tsubota1, Shigeto Shimmura1, Yumi Matsuzaki3
1 Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, 
Japan
2 Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo 
160-8582, Japan 
3 Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan 
4 Bridgestone Laboratory of Developmental and Regenerative Neurobiology, Keio 
University School of Medicine, Tokyo 160-8582, Japan 
5 Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University 
School of Medicine, Tokyo 160-8582, Japan 
6 Division of Hematology, Department of Internal Medicine, Keio University School of 
Medcine
Correspondence should be addressed to Yumi Matsuzaki (pentadou@gmail.com) and 
Shigeto Shimmura (shige@z8.keio.jp) 
Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, 
Shinjuku-ku, Tokyo160-8582, Japan (Tel: +81-3-5363-3565, Fax: +81-3-5363-3566) 
*Both authors contributed equally to the manuscript 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.6
84
3.
1 
: P
os
te
d 
28
 J
an
 2
01
2
2 
 
Chronic graft-versus-host disease (cGVHD) is a complication after minor antigen 
mismatched bone marrow transplantation (BMT) characterized by an 
autoimmune-type reaction in various organs.  Aberration in T cell regulation is 
involved, with donor mesenchymal stem cells (MSCs) playing a possible role in 
immunomodulation.  In a minor-antigen mismatched mouse BMT model, 
transplantation of mismatched, but not syngeneic MSCs triggered the onset of cGVHD, 
and was associated with fibrosis, increased IL-6 secretion, decreased Foxp3+ regulatory 
T cells and increased Th17 in the peripheral blood.  Mismatched MSCs alone were 
sufficient to induce cGVHD, while removal of donor MSCs rescued mice from cGVHD.  
RAG2 knockout recipient mice did not suffer cGVHD, indicating that host T cells were 
involved.  Residual host-derived T cells were significantly higher in cGVHD patients 
compared to non-cGVHD patients.  In conclusion, donor MSCs react with residual 
host T cells to trigger the progression of cGVHD. 
Chronic GVHD (cGVHD) has distinct clinical findings, which resemble features of 
autoimmune disease such as systemic sclerosis or Sjögren’s syndrome involving exocrine 
glands 1,2, and is believed to be distinct from the potentially lethal acute form of GVHD.  
This autoimmune phenotype has been attributed to donor-derived T cells that escape 
negative selection by the host thymus damaged by acute GVHD 3,4.
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Bone marrow transplantation with 8 week-old donor B10.D2 (H-2d) mice and 
recipient BALB/c mice (H-2d) has been reported as a MHC-compatible, minor antigen 
(miHA)–incompatible model of cGVHD (Supplementary Fig. 1a) 5.  The phenotype of the 
mice closely resembles clinical samples of patients suffering from cGVHD (Supplementary 
Fig. 1b).  Signs of cGVHD appear by 3 weeks after BMT, and progresses to full-blown 
disease by 8 weeks characterized by low tear volume and excessive fibrosis of the lacrimal 
gland, conjunctiva, salivary gland, skin, lung, liver and intestine (Supplementary Fig. 1c). 
Accumulation of donor-derived fibroblasts in fibrotic lesions surrounding exocrine ducts 
was observed (Supplementary Fig. 1d), which was similar to human patients as shown in 
our previous report 6.  These results suggested that donor-derived fibroblasts were part of 
the pathological process leading to cGVHD. 
Multipotent mesenchymal stem/stromal cells (MSCs) in the bone marrow 
differentiate into several mesenchymal lineages such as fibroblasts, adipocytes, osteocytes 
and chondrocytes 7,8.  However, the in vivo dynamics of MSCs after WBMT are still 
unknown due to the lack of specific markers.  Furthermore, a crucial step involving in
vitro expansion was required to isolate these cells, which may modify their phenotype and 
function 9.  Most current information on MSCs comes from such in vitro studies of 
adherent cells referred to as fibroblast CFUs (CFU-Fs) 7,8,10,11, which are a heterogeneous 
population of cells at best.  Tracing the fate of MSCs following transplantation is 
complicated due to these reasons. We have recently succeeded in prospectively isolating 
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murine MSCs based on their expression of PDGF receptor α and Sca-1 (PDGFRα+/ Sca-1+
(PαS) cells) 12.  Isolated PαS-MSCs without in vitro expansion can differentiate into 
hematopoietic niche cells, osteoblasts and adipocytes after systemic in vivo transplantation 
13.  In this study, we sought to answer the debated role of donor MSCs in the pathogenesis 
of the autoimmune-like phenotype of cGVHD using prospectively isolated MSCs and 
HSCs in a mouse model of cGVHD. 
RESULTS 
Minor antigen mismatched HSC and MSC co-transplantation 
In order to elucidate the role of donor-derived fibroblasts, we first established a modified 
cGVHD model by co-transplanting isolated hematopoietic stem cells (HSCs) and MSCs.  
PαS-MSCs and side population (SP) HSCs (Supplementary Fig 2a) from B10.D2 bone 
marrow were individually isolated by cell sorter and systemically co-transplanted into 
BALB/c mice (Fig. 1a).  Unlike the original WBMT model which co-transplanted splenic 
cells, the graft in our experiments does not include mature, differentiated cells both in the 
hematopoietic and non-hematopoietic fractions.  In addition, there is lineage exclusivity, 
where all hematopoietic lineage cells are derived from SP-HSCs, while non-hematopoietic 
cells are of donor PαS-MSC origin 13,14.  This modified co-transplantation model induced 
systemic fibrosis (Fig. 1b), which was indistinguishable from that of cGVHD induced by 
the conventional WBMT model (Supplementary Fig 1c).  In addition, cells double positive 
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for the fibroblast marker HSP47 and EGFP were detected in cGVHD tissue when EGFP+
PαS-MSCs were transplanted with wild type B10.D2 SP cells (Fig. 1c, d).  Approximately 
42.9 ± 7.3% of the HSP47+ fibroblasts in cGVHD tissue were GFP+, indicating that the 
majority of fibroblasts were derived from donor PαS-MSCs (Fig.1d).  On the other hand, 
a notable number of cells derived from mismatched donor SP-HSCs also migrated to 
fibrotic lesions, but none of the cells expressed HSP47 (Fig. 1c, e).  This shows that the 
donor fibroblasts originated from purified MSCs but not HSCs.
Mismatched PαS-MSCs induce cGVHD
In order to determine if either mismatched MSCs or HSCs play a dominant role in cGVHD, 
we performed the following transplantation.  BALB/c mice were transplanted with a 
combination of BALB/c (syngeneic) HSCs and B10.D2 (mismatched) MSCs, or vice-versa 
(Fig. 2a).  Surprisingly, progressive fibrosis was observed in mice receiving mismatched 
MSCs combined with syngeneic HSCs (Fig. 2b, Supplementary Fig. 2b, lower).  On the 
other hand, recipients of mismatched HSCs combined with syngeneic MSCs were either 
normal, or only suffered a forme-fruste form of the disease (Fig. 2b, Supplementary Fig. 2b, 
upper). Affected lesions in the mismatched MSC transplanted-mice had significantly higher 
HSP47+ fibroblasts (Fig. 2c, Supplementary Fig. 2c) and lacrimal gland function was 
reduced as quantitated by tear volume (Fig. 2d).  The severity of cGVHD-associated 
fibrosis triggered by mismatched MSCs was dose dependent on the amount of transplanted 
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MSCs (Fig. 2e), which taken together, strongly suggest that the presence of mismatched 
MSCs triggers the onset of cGVHD. 
Deletion of PαS-MSCs prevents cGVHD
To confirm the requirement of mismatched MSCs for the onset of cGVHD, we tried 
removing PαS cells from donor bone marrow (MSC(-)) to see if this prevents the onset of 
cGVHD.  As expected, MSC(-) mismatched WBM transplanted recipients showed 
minimal pathological changes (Fig. 3a-b, Supplementary Fig. 3a).  HSP47+ fibroblasts 
associated with fibrotic lesions were also reduced (Fig. 3c-d, Supplementary figure 3b).  
Mean tear secretion volume in mismatched WBM-transplanted mice gradually decreased 
reaching statistical significance at 8 weeks after transplantation, but was preserved in the 
MSC(-) group (Fig. 3e).  Therefore, the histological change and functional loss of the 
lacrimal gland was rescued by MSC depletion from donor cells, suggesting that 
mismatched MSCs alone can cause cGVHD. 
Host T cells are required for the progression of cGVHD 
The progression of cGVHD in this mouse model is T cell-dependent as shown by the lack 
of fibrotic lesions when BALB/c background nu/nu mice were used as recipients of 
mismatched B10.D2 MSCs (Supplementary Fig. 4).  The next question was to determine 
whether these pathogenic T cells were of donor origin, or residual host T cells that have lost 
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self-tolerance. It is conceivable that mismatched donor MSCs integrate into the thymic 
epithelium and induce donor HSC-derived T cells that recognize host tissue as non-self 
within this time frame.  However, this is unlikely since EGFP+ MSC-derived cells did not 
integrate into the cortical region of the thymic epithelium 3 weeks after transplantation 
(Supplementary figure 2d).  On the other hand, mature T cells often escape from radiation 
damage and remain as residual host-derived T cells in the peripheral blood of recipient 
mice 15.  Therefore, both host-derived T cells and donor HSC-derived T cells are believed 
to exist in the cGVHD mice.  To determine T cell origin, we used BALB/c background 
RAG2KO mice that lack T and B cells as recipients or donors of HSCs.  The former 
would lack recipient T cells, while the latter would not provide donor T cells after 
transplantation.  At 3 weeks after transplantation, fibrosis due to GVHD was limited, 
indicating that mismatched MSCs alone do not induce clinical signs of cGVHD without 
competent recipient-derived T cells (Fig. 4a).  On the other hand, when mismatched MSCs 
and RAG2KO mouse-derived HSCs were transplanted into wild type BALB/c recipients, 
cGVHD-associated fibrosis was observed (Fig. 4b) also shown by a statistically higher 
number of HSP47+ fibroblasts (Fig. 4c).  These results suggest that purified mismatched 
PαS-MSCs reacted with recipient mature T cells to trigger cGVHD fibrosis, at least during 
the early onset of disease.     
Activated T-cells in mismatched MSC recipients  
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The fact that mature host T cells acquire the ability to react to auto-antigens during cGVHD 
is reminiscent of an autoimmune process, and therefore, the following in vitro experiments 
were done to observe T cell activation.  Various sources of T cells (from mismatched 
MSC-transplanted, autologous MSC-transplanted, wild type B10.D2 or wild type BALB/c 
mice) were co-cultured with freshly isolated PαS-MSCs or splenic dendritic cells (DC) 
from BALB/c or B10.D2 mice.  Thy-1+ T cells derived from mismatched 
MSC-transplanted recipients proliferated in response to not only mismatched B10.D2 
MSCs, but also to syngeneic BALB/c MSCs confirming the auto-reactive nature of 
recipient T cells (Fig. 5a).  In addition, naïve T cells from wild type B10.D2 or BALB/c 
mice proliferated at basal levels in response to either type of MSCs, but not to DCs.  We 
also detected elevated levels of IL-6 in the supernatant of co-cultures with T cells from 
mismatched MSC transplanted recipients and B10.D2 or BALB/C MSCs (Fig 5b).  In 
contrast, IL-6 levels remained low when T cells of all sources were co-cultured with 
autologous or mismatched DC, indicating that antigens expressed in MSCs, but not in DCs, 
trigger the oligo-clonal auto-reactive T cell response in the recipient.  Flowcytometry 
revealed that both PαS-MSCs and T cells from mismatched MSC-transplanted recipients 
produce IL-6 when reacted with B10.D2 MSCs in vitro (Fig 5c).  Serum levels of IL-6 
also increased in recipient mice transplanted with mismatched MSCs starting at 3 weeks 
after transplantation (Fig. 5d), indicating that systemic levels of IL-6 increased with the 
early onset of cGVHD.  These results clearly show that mismatched MSCs can activate 
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host T cells in vivo, leading to the contrasting T cell proliferation and IL-6 production of T 
cells and MSCs in vitro.
Temporal increase of regulatory T-cells is suppressed with mismatched MSC 
Increased IL-6 during an autoimmune process leads to the induction of Th17 cells and a 
decrease in regulatory T cells (Tregs) 16.  We therefore further examined whether similar 
events occur after mismatched MSCs transplantation.  We found that CD4+CD25+Foxp3+
Tregs in peripheral blood transiently increased following lethal irradiation and syngeneic 
transplantation of MSCs or WBMT which recovered to basal levels by 8 weeks (Fig. 5e, f).  
This transient increase in Tregs, reaching statistical significance at 3 weeks, was not 
observed after mismatched MSC or WBM transplantation (Fig. 5f).  This was followed by 
an increase of Th17 cells (Fig. 5g) in both the mismatched WBMT and MSC groups 
reaching statistical significance compared to syngeneic controls at 3 weeks in the WBMT 
group (Fig 5h-left), and 8 weeks in the MSC mismatch group (Fig 5h-right).  These 
results suggest that mismatched MSCs suppress Treg production during the early phases of 
cGVHD, leading to the increase of Th17 cells during later stages.  The results so far show 
that the transplantation of mismatched MSCs leads to pathological changes in major organs 
similar to autoimmune disease with inflammation due to Th17 cells via suppression of 
transient increase in Tregs. 
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Detection of recipient-derived T cells in cGVHD patients 
In human BMT patients, it is believed that host T cells are completely replaced by 
donor-derived T cells in the cGVHD phase 17.  However, our results using the cGVHD 
model mouse showed the role of recipient-derived T cells in the onset of cGVHD.  In 
order to confirm if our findings also applied to human cGVHD cases, we performed FISH 
for X- and Y-chromosomes using peripheral blood mononuclear cell samples (PBMC) from 
cGVHD and non-cGVHD patients who received sex-mismatched WBM transplantation 
(Fig. 6a).  The proportion of recipient-derived T cells in PBMC ranged from 5.6 to 16.7% 
(9.04.4%) in 5 patients who developed cGVHD, while recipient-derived T cells ranged 
from 0.4 to 3.7% (2.11.4) in 4 patients who did not develop GVHD (Supplementary 
Table).  In accordance to our hypothesis, the frequency of recipient-derived CD3+ T cells 
was statistically higher in cGVHD patients compared to non-cGVHD patients (Fig. 6b). 
DISCUSSION 
The therapeutic potential of MSCs was first reported in a case of acute GVHD transfused 
with haploidentical MSCs with dramatic improvement of symptoms 18.  This was followed 
by a phase II trial of MSC infusion for severe acute GVHD anticipating that allogeneic 
MSCs play an immunosuppressive role following BMT 19.  While the lethal nature of 
acute GVHD may necessitate such and other therapeutic trials 20, the mechanisms involved 
are unknown other than reports suggesting the release of immunomodulatory cytokines by 
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MSCs trapped in the lung 12,21-23.  The pros and cons of MSC therapy should be carefully 
weighed before further clinical use of these cells since they seem to exert different results 
in acute and chronic forms of GVHD.  Furthermore, since it is now possible to 
prospectively isolate MSCs, a thorough re-evaluation of previous works that have relied on 
in vitro expansion for the collection of MSCs is required.   
We found that massive fibrosis in lacrimal and salivary gland, skin, lung, liver 
and intestine in a cGVHD mouse model was attributed to donor derived MSCs, and not 
mismatched HSCs.  Our results also suggested that radio-resistant residual recipient T 
cells, but not donor-HSC derived de novo T cells, were activated following mismatched 
MSC transplantation.  The development of cGVHD in our model started as early as 3 
weeks, although at least 4 weeks are required for maturation of T cells to appear in the 
peripheral blood following purified HSC transplantation 24.  Furthermore, we found a 
statistically higher ratio of recipient-derived T cells remaining in patients suffering from 
cGVHD compared to non-cGVHD patients following WBMT.  In view of all the 
supporting evidence, we conclude that residual host T cells are responsible for the 
pathogenesis of cGVHD in both this cGVHD animal model, as well as in human cGVHD 
patients.  These results are compatible with other reports showing how residual recipient 
CD4+ T cells regulate cGVHD 15,25.
Previous reports presented data showing the lack of lymphocyte activation by 
MSC co-cultures as evidence for the immuno-suppressive properties of MSCs 26,27.  In 
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contrast, our results show that donor-derived MSCs react with host-derived T cells in the 
pathogenesis of the autoimmune type pathology observed in cGVHD.  Thy-1+ T-cells 
isolated from mice after mismatched BMT were activated by PαS-MSCs in vitro, as shown 
by enhanced proliferation and IL-6 secretion.  The onset of cGVHD is associated with 
progressive loss of CD4+CD25+Foxp3+ Tregs during episodes of acute GVHD 28.  We 
found a similar autoimmune response in cGVHD mice characterized by repression of Treg 
induction, followed by an increase in Th17 effector cells without an episode of acute 
GVHD.  In summary, donor PαS-MSCs are the initial trigger of events leading to 
increased levels of circulating IL-6, followed by a decrease in Tregs, and conversely an 
increase in Th17 cells.  Activation or maturation of MSC-derived cells is probably also 
involved since accumulation of donor-derived fibroblasts was not observed in syngeneic 
transplantation, where cGVHD does not occur (Supplementary Fig. 5).  
Since naïve T-cells responded to PαS-MSCs in vitro at low levels, we speculate 
that auto-reactive T cells that are only present in basal levels under normal conditions 29
recognize minor differences between B10.D2 and BALB/c MSCs.  The auto-antigen 
responsible for the autoimmune type reaction still needs to be identified.  A common 
antigen specifically expressed in MSCs of B10.D2 and BALB/c with different isoforms or 
SNIPs, is one of the most probable candidates.  The lack of cGVHD following 
mismatched HSC transplantation suggests that hematopoietic lineage cells, including DCs, 
did not express such a molecule.  The same cGVHD phenotype was observed when host 
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and recipient were reversed (ie. BALB/c MSCs transplanted to B10.D2 recipients, data not 
shown).  This implies that both B10.D2 and BALB/c MSCs can be a primary inducer 
against mismatched recipient T cells.  Using MHC matched strains of mice other than 
B10.D2 and BALB/c is required to further confirm generality.  Recently, the role of host 
non-hematopoietic antigen presenting cells (APCs), and not hematopoietic professional 
APCs, including DCs, was shown to be responsible for the progression of lethal acute 
GVHD 30.  These non-professional APCs were suggested to be mesenchymal cells due to 
the expression of αSMA.  Our results clearly showed that donor-derived MSCs were 
responsible for the onset of non-lethal cGVHD.  These findings together strongly 
challenge conventional paradigms of GVHD.  The source of mesenchymal cells (ie. donor 
or host) responsible for the initial trigger may be used to differentiate the acute and chronic 
forms of GVHD, which until recently have been differentiated by the timing of onset 
empirically set at 100 days after transplantation.  There are other limitations to the data 
presented in this study.  Namely, although the PαS fraction contains a 2x105-fold higher 
concentration of clonogenic MSCs compared to WBM, the population is still not “pure”.  
Therefore, it may include progeny of both stimulatory cells that interact with T cells and 
fibroblasts that directly contribute to tissue fibrosis.  In order to clarify this point, further 
purification of MSCs will be necessary. 
 The clinical implications of our study cannot be ignored, for cGVHD is a major 
complication that can severely compromise quality of life in patients receiving bone 
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marrow transplants.  Our data clearly indicated that depletion of MSCs from donor tissue 
significantly reduced cGVHD-related fibrosis in all organs examined and rescued mice 
from lacrimal gland dysfunction associated with cGVHD.  Targeted therapy against 
specific cytokines such as IL-6 was reported as a feasible therapy for preventing cGVHD 31.
However, we have identified selective markers for isolating MSCs in humans (unpublished 
data).  With the availability of markers to prospectively isolate human MSCs, excluding 
the MSC fraction from donor cells may be more effective in preventing the onset of 
cGVHD.  A recent report also supports our hypothesis where the incidence of cGVHD is 
less following cord blood transplantation 32,33.  Since we have found that MSCs are rarely 
detected in cord blood (unpublished data), this may explain the lower frequency of cGVHD 
in CBT.  A prospective clinical study investigating the onset of cGVHD in association 
with the amount of MSCs that were included in the donor BM or cord blood will be 
necessary to confirm our hypothesis.  
In conclusion, transplantation of minor antigen-mismatched MHC-compatible 
MSCs interact with residual host T cells to induce the auto-immune phenotype observed in 
cGVHD, and strategic removal of these cells may be an effective way to prevent suffering 
due to cGVHD.
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METHODS
Mice.
B10.D2, BALB/c and Nude mice 8-10 week of age were purchased from Sankyo 
Laboratory, Inc. (Tokyo, Japan).  B10.D2 GFP mouse were obtained by backcrossing of 
B10.D2 mice with C57BL/6 GFP mice (Japan SLC Ltd).  The 10th generation of 
backcrossed B10.D2 GFP progenies was used for experiments.  RAG2KO on BALB/c 
background were kindly provided from Dr. Shigeo Koyasu (Keio University).  The mice 
were kept under specific pathogen-free conditions in our animal facility at Keio University 
School of Medicine.  All experimental procedures and protocols were approved by the 
ethics committee of Keio University and were in accordance with the Guide for the Care 
and Use of Laboratory Animals.    
Isolation of SP-HSCs  
Bone marrow cells, suspended at 1x106 cells per milliliter in calcium- and magnesium-free 
Hanks balanced salt solution (HBSS) supplemented with 2% fetal calf serum, 10 mM 
HEPES and 1% penicillin/streptomycin (HBSS+) were incubated with 5 μg /ml Hoechst 
33342 (Sigma Aldrich) for 60 minutes at 37°C.  The side population (SP) was sorted as 
described previously 34.
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Isolation of CD45-TER119-PDGFRα+Sca-1+ cells (MSCs) 
Purified MSCs were isolated by flowcytometry as described previously 12,13. Briefly, 
femurs and tibias were dissected and crushed with a pestle. The bone marrow was gently 
washed in HBSS+. Collagenase (0.2%) was used to digest the minced tibia and femur in 
HBSS+ without fetal bovine serum at 37°C for 1 hour.  After red cell lysis, the residual 
cells were stained with FITC-labeled anti-Sca-1 (Ly6A/E), APC-labeled anti-PDGFRα
(APA-5), PE-labeled anti-CD45 (30-F-11), and PE-labeled anti-TER119 (TER-119) (all 
from e-Bioscience). Analysis and sorting were performed on a triple-laser MoFlo 
flowcytometer (Beckman Coulter).  CD45- TER119- PDGFRα+ Sca-1+ cells were routinely 
prepared at 99% purity by this method. 
MSCs and HSCs Co-transplantation
In all transplantation experiments, 1x104 PS-MSCs and 1x103 SP-HSCs (Supplementary 
Fig. 2a) were intravenously injected into the tail vein of etherized recipient mice that had 
been lethally irradiated with a dose of 10.5 Gy (200 μl per mouse) as indicated in our 
previous studies 12,34.
T-cell isolation and co-culture with MSCs 
Spleens were obtained from mice that received B10.D2 MSC or BALB/c MSC transplants.  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
12
.6
84
3.
1 
: P
os
te
d 
28
 J
an
 2
01
2
17 
 
T cells were purified from the spleens by anti-CD90.2 monoclonal antibody 
(mAb)-conjugated microbeads (Miltenyi Biotec) according to the manufacturer’s 
instructions.  The purity was consistently > 98%.  T cells were cultured alone or 
co-cultured with PαS-MSCs at a ratio of 10:1 (T cells: MSCs). 
Proliferation assay  
MSCs were plated at 1x104 cells/ well into 96-well plates in triplicate, which were 
irradiated at 52 Gy after adherence.  1x105 purified mouse T cells were added to each well.  
On the fourth day, 5-bromo-2’-deoxyuridine (BrdU) was added.  Twenty-four hours later, 
BrdU uptake was quantified 35 by cell proliferation enzyme-linked immunosorbent assay 
(ELISA) using a BrdU Kit (Roche Applied Science).  The supernatant of the co-cultures 
was subjected to IL-6 ELISA using commercial kit (BD Biosciences).  T cells and MSCs 
without irradiation after co-cultures were used for FACS analysis for analyzing the cellular 
source of IL-6 production.  
Serum cytokine analysis
Serum was collected from mice using retro-orbital beads 31.  The concentration of IL-6 
in the supernatants was determined by ELISA using a specific kit, according to the 
manufacturer’s instructions (BD Biosciences).  The experiments were performed in 
triplicate. 
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Flowcytometry analysis for intracellular cytokine IL-6 and IL-17 
Two × 106 spleen cells were stimulated with 10 ng/mL phorbol myristate acetate (PMA) 
(Sigma) and 10 ng/mL inomycin (Sigma) in the presence of the Golgi inhibitor Brefeldin 
(Sigma) (10 μg/mL) for 4 hours.  The cells were then stained with FITC-labeled anti-CD4 
(GK 1.5, e-Bioscience) and PE-labeled anti-IL-6 (MP5-20F3, BD PharmingenTM) or 
APC-labeled anti-IL-17 (eBio17B7, e-Bioscience) as described 36.  PE-labeled IgG2a, 
FITC-labeled IgG1, and APC-labeled IgG2a and IgG2k were used as isotype controls (all 
from e-Bioscience).  Cells were analyzed on a FACScan with Cellquest software 
(Beckton Dickinson).  For the co-cultures with T cells and MSCs, T cells were stimulated 
with Brefeldin (10 μg/mL) alone for 4 hours. 
Foxp3 staining 
Whole blood samples were co-stained with anti-CD4-FITC and anti-CD25-PE (PC61.5).  
After fixation and permeabilization, cells were stained with APC-labeled anti-Foxp3 mAb 
(FJK-16s) (all mAbs were from e-Bioscience) as described 28.  Rat IgG2a, κ was used as 
an isotype control. 
CD3 immnunostaing and FISH for human PBMCs 
cGVHD was diagnosed according to the previously reported criteria 2.  PBMCs from sex 
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mismatched BMT recipients were obtained by Ficoll-Paque gradient centrifugation.  
Cytospined 2x105 PBMCs were subjected to FITC-conjugated CD3 immunostaning (OKT3, 
Biolegend) and Y-chromosome or X-chromosome FISH using a DNA probe (VysisTM,
Abbot Japan) with TO-PRO-3 (Molecular Probe) as described 6.  Majority of PBMCs (> 
99%) on the slides were confirmed as CD3+ T cells. Two observers (Y.O. and S.S.) blindly 
evaluated at least 500 non-overlapping T cells on coded slides.  The frequency (%) of 
recipient-derived T cells was calculated according to the following formula; for analyzing 
the number of X-FISH+ or Y-FISH+ recipient-derived T cells, at least five different fields of 
two specimens at x200 magnification were analyzed under a confocal laser-scanning 
microscope (LSM 700, Carl Zeiss).  All studies with human sample were under approvals 
of Institutional Review Board at Keio University for human subjects.   
 
Statistics
Two-tailed Student’s t-test (Excel 2007) was used to analyze the number of HSP47+
fibroblasts per field, cytokine serum levels, and cell proliferation and cytokine production 
in co-cultures.  Differences were considered significant when p < 0.05. Data presented as 
mean ± SD. 
Additional methods. Whole bone-marrow transplantation, tissue processing, 
immunostaining, Y-chromosome FISH for tissue section and measurement of tear secretion 
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volume are described in the Supplementary Methods.
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Figure legends
Figure 1: Modified cGVHD model by co-transplanting isolated HSCs and MSCs
(a) By using a cell sorter, PαS-MSCs (PDGFRα+/ Sca-1+) and HSCs (side population (SP) 
cells) from B10.D2 bone marrow were individually isolated and systemically 
co-transplanted into BALB/c mice.  (b) Representative images of systemic fibrosis 
(Mallory staining, blue) in various organs of PαS-MSCs and SP-HSCs co-transplanted 
recipients at 3 or 8 weeks.  Double arrows in skin indicate the thickness of epidermal 
region leading to the loss of adipose tissue in the mismatched MSC group.  Scale bar, 100 
μm (Skin, Lung, Liver, 50 μm).  (c) Transplantation scheme of EGFP+ labeled B10.D2 
PαS-MSCs or SP-HSCs.  Each was co-transplanted into wild type BALB/c along with 
unlabeled SP-HSCs or PαS-MSCs respectively.  (d, e) Fluorescence microscopic images 
of GVHD target tissues from recipient mice stained for EGFP (green), HSP47 (red) and 
with DAPI (blue)..  The data in b, d and e from two replicate experiments (n = 3 per 
group).  Scale bar, 20 μm.
Figure 2: Mismatched PαS-MSCs induced cGVHD
(a) BALB/c mice were transplanted with a combination of BALB/c HSCs and B10.D2 
MSCs, or vice-versa.  (b) Mallory staining of lacrimal gland, liver and intestine from 
recipient mice either of mismatched or syngeneic MSC at 3 or 8 weeks after transplantation.  
Data from 5 independent experiments (n = 4-5 per group).  Scale bar 100 μm (intestine, 50 
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μm).  (c) Semi-quantitative histopathology of HSP47+ fibroblasts in the tissues from 
Syngeneic MSC (blue) and Mismatched MSC (red) transplanted-mice.  Data from five 
different fields in two replicate experiments.  Error bars indicate s.d. ∗P<0.05, ∗∗P<0.01. 
(d) Lacrimal gland function was quantitated by tear volume in the syngeneic MSC (blue) 
and mismatched MSC transplanted-mice (red) at 8 weeks after transplantation.  Data from 
two replicate experiments (n=3-5 per group), ∗P<0.05.  (e) Mallory staining of lacrimal 
gland tissue sections of BALB/c recipients at 3 weeks after transplantation, which were 
transplanted with 5x102, 2x103, 8x103, or 1.6x104 mismatched PS-MSC or 1.6x104
syngeneic PS-MSC (n=3 per group).  Scale bar, 100 μm.
Figure 3: Deletion of PDGFRα+Sca-1+ MSCs prevents cGVHD.
Mallory staining of lacrimal gland (a) and salivary gland (b) tissue sections of BALB/c 
mice that received either syngeneic whole bone marrow (WBM), mismatched WBM, or 
PαS-MSCs depleted mismatched WBM (MSC(-)) at 8 weeks after transplantation.  
Representative data from three replicate experiments (n=5 per group).  Scale bar, 100μm.  
(c, d) Semi-quantitative histology of HSP47+ fibroblasts in mismatched WBMT (red), 
syngeneic control (blue) and MSC-depleted mismatched WBMT(green). The data in c and 
d was collected from 5 different fields in two replicate experiments. Error bars indicate 
mean ± s.d.  ∗P<0.01, ∗∗P<0.001.  (e) Tear secretion volume 8 weeks after mismatched 
WBMT (red) compared with syngeneic controls (blue) and MSC-depleted mismatched 
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WBMT (green) (n=3 per group).  Error bars indicate mean ± s.d.  ∗P<0.05.
Figure 4: Host T cells are required for the progression of cGVHD
(a) Mallory staining of lacrimal gland, salivary gland, liver and intestine of recipient 
RAG2KO mice at 3 and 8 weeks after transplantation of mismatched PαS-MSCs and 
syngeneic BALB/c SP cells (B10 MSC + BALB/c HSC into RAG2KO).  Scale bar, 100 
μm.  (b) Typical signs of tissue fibrosis in B10.D2 MSC + RAG2KO SP cell transplanted 
BALB/c recipient mice.  The data in a and b was collected from two replicate experiments 
(n = 3 per group).  Scale bar, 100 μm ∗P<0.01, ∗∗P<0.001.  (c) Quantification of 
HSP47+ fibroblasts per field in B10 MSC with RAG2KO HSC into BALB/c group (red) 
and B10 MSC with BALB/c into RAG2KO group (blue).  Data from five different fields 
in two replicate experiments.  Error bars indicate s.d.  ∗P<0.01, ∗∗P<0.001.
Figure 5: T cells following mismatched BMT are activated by PαS-MSCs
T cell proliferation (a) and IL-6 production (b) following co-culture with PαS-MSCs or 
splenic DCs.  Bars indicate; T cells from mismatched PαS-MSC transplanted BALB/c 
(white), syngeneic PαS-MSC transplanted BALB/c (black), wild-type B10.D2 (dark gray) 
and wild-type BALB/c (light gray).  (a) T cell proliferation was evaluated by BrdU uptake 
24 hrs after incubation.  Results are expressed as the mean value of OD 450 nm (± SD) 
obtained from triplicate cultures and are representative of two independent experiments.  
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∗P<0.05, **P<0.01.  (b) IL-6 concentration in the supernatants of co-cultures was 
measured by ELISA at 24 hours after stimulation.  Data from triplicate culture of two 
independent experiments.  Error bars indicate s. d. ∗P<0.05, **P<0.01.  (c)
Representative flowcytometry analysis of intracellular IL-6 in CD3ε+ T cells and Sca-1+
MSCs at 24 hours after co-culture.  Dot plots of mAb stained sample (black) and Isotype 
control (light gray) were shown.  (d) IL-6 serum concentration after mismatched MSC and 
syngeneic MSC transplantation was measured by ELISA.  Data from two independent 
experiments (n= 3).  Error bars indicate s. d. ∗P<0.05.  (e) Representative flowcytometry 
analysis of CD25 and Foxp3 in CD4+ splenic cells derived from mismatched WBMT mice 
(right) or syngeneic control mice (left) at 3 weeks.  (f) Mean percentage of 
CD4+CD25+Foxp3+ cells after WBMT (left) or MSCT (right) were serially measured by 
flowcytometry.  (g) Representative flowcytometry analysis of CD4 and IL-17 for splenic 
cells from mismatched WBMT or syngeneic control mice.  (h) Mean percentage of 
CD4+IL-17+ cells after syngeneic or mismatched WBMT (left) and MSCT (right) at 3 and 8 
weeks after transplantation was measured by flowcytometry.  (e-h) Data from 3 
independent experiments (n=3-5 per group).  Error bars represent SD.  *P<0.05,
**P<0.01.
Figure 6: Detection of recipient-derived T cells in cGVHD patients
(a) FISH for X- and Y-chromosomes using peripheral blood mononuclear cell samples 
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(PBMC) from cGVHD and non-cGVHD patients who received sex-mismatched WBM 
transplantation.  Scale bar, 100 μm.  Arrows indicate recipient-derived T cells. (X-FISH, 
two green signals; Y-FISH, one red signal).  (b) Average amount of recipient-derived T 
cells in the peripheral blood of cGVHD (n=5) and non-cGVHD (n=4) patients. *P<0.05
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